Aaron Lindstrom

● Designed and synthesized 60+ small molecule peptides as covalent and non-covalent inhibitors of SARS-COV2 MPro for a project that delivered the lead preclinical candidate (AB-343). ● Synthesized 50+ nucleosides and nucleoside prodrugs targeted to SARS-COV2 NSP12 polymerase, which resulted in one patent and one manuscript in progress. ● Applied structure-based design to convert crystallographic information into novel chemical entities with improved on-target activity. ● Collaborated with a cross-functional team of computational chemists, biologists, DMPK / ADME experts, and clinical professionals to move projects forward and design improved molecules. ● Regularly presented work during project/departmental meetings and contributed to patent filings. ● Worked with external CRO partners to complement in-house synthesis, overcome synthetic challenges, and meet project goals and timelines. ● Maintained electronic and hardcopy notebooks of syntheses and final compounds. ● Utilized biological, ADME, and in silico data to develop hypotheses and propose target molecules. ● Executed gram-scale production of lead compounds in support of project goals.

● Synthesized 150+ small molecule amphiphiles, lipids, and peptides to improve on-target activity, tumor selectivity, and ADME properties with a focus on immuno-oncology. ● Produced NR4A1, SEMA3C, and STAT3 PROTAC degraders and progressed several molecules into in vivo tumor studies, resulting in one published paper and several manuscripts in progress. ● Employed in silico tools to screen compound libraries and identify unique protein-ligand interactions to discover potent STING, NR4A1, and SEMA3C interactors. ● Skilled in the preparation of nanomaterials and encapsulation of small molecules through solvent evaporation and lyophilization and their analysis by DLS, SEC, HPLC, SEM, and XRD.

● Manufactured lead compounds and formulations on scale under GLP and cGMP conditions for IND-enabling studies, in preparation for their transition into clinical trials. ● Received NIH SBIR Phase I/II funding to mature existing technologies in expectation of clinical trials. ● Served as Chief executive Officer and represented Theranostec Inc. at investor conferences and pitch competitions. ● Initiated and maintained collaborations with industry and clinical partners to aid in company development and move our therapeutics from bench to bedside.

● Identified new ebolavirus therapies by creating 50+ derivatives of natural products and testing them to develop a novel structure-activity relationship, which resulted in two publications and one patent. ● Established innovative synthetic routes and resolved problems in the synthesis of several complex heterocyclic compounds to enhance chemical variety and yields. ● Designed original biochemical and cell-based assays to assess drug effects on endosomal pathways to inform structure-activity relationships for further refinement. ● Organized and led weekly meetings with collaborators to coordinate experiments, overcome setbacks, and drive projects to completion.